AADi Bioscience/AADI

$1.84

1.09%
-
1D1W1MYTD1YMAX

About AADi Bioscience

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.

Ticker

AADI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Neil Desai

Employees

75

Headquarters

Pacific palisades, United States

AADi Bioscience Metrics

BasicAdvanced
$47M
Market cap
-
P/E ratio
-$2.55
EPS
0.66
Beta
-
Dividend rate
$47M
0.66363
$8.49
$1.55
336K
5.161
4.862
-48.86%
-58.22%
-56.39%
1.988
0.524
0.524
26.97%
3.08%
17.53%

What the Analysts think about AADi Bioscience

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 3 analysts.
497.83% upside
High $14.00
Low $5.00
$1.84
Current price
$11.00
Average price target

AADi Bioscience Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-343.39% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5.3M
-15.87%
Net income
-$18M
12.35%
Profit margin
-343.39%
33.54%

AADi Bioscience Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.84%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.67
-$0.60
-$0.60
-$0.68
-
Expected
-$0.62
-$0.72
-$0.65
-$0.64
-$0.69
Surprise
7.72%
-17.13%
-7.41%
5.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for AADi Bioscience stock?

AADi Bioscience (AADI) has a market cap of $45M as of May 26, 2024.

What is the P/E ratio for AADi Bioscience stock?

The price to earnings (P/E) ratio for AADi Bioscience (AADI) stock is 0 as of May 26, 2024.

Does AADi Bioscience stock pay dividends?

No, AADi Bioscience (AADI) stock does not pay dividends to its shareholders as of May 26, 2024.

When is the next AADi Bioscience dividend payment date?

AADi Bioscience (AADI) stock does not pay dividends to its shareholders.

What is the beta indicator for AADi Bioscience?

AADi Bioscience (AADI) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the AADi Bioscience stock price target?

The target price for AADi Bioscience (AADI) stock is $11, which is 497.83% above the current price of $1.84. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell AADi Bioscience stock

Buy or sell AADi Bioscience stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing